Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 145 of the 146 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) remains a major cause of morbidity and mortality worldwide, and despite extensive research, only a few drugs are available for management of the disease. One strategy has been to up-regulate cholinergic neurotransmission to improve cognitive function, but this approach has dose-limiting adverse effects. To avoid these adverse effects, new drugs that target specific receptor subtypes of the cholinergic system are needed, and the M1 subtype of muscarinic acetylcholine receptor (M1-mAChR) has been shown to be a good target for this approach. By using several strategies, M1-mAChR ligands have been developed and trialled in preclinical animal models and in human studies, with varying degrees of success. This article reviews the different approaches to targeting the M1-mAChR in AD and discusses the advantages and limitations of these strategies. The factors to consider in targeting the M1-mAChR in AD are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“M1-mAChR positive allosteric modulators (M1-PAMs), such as BQCA (53) and PF06764427 (54), achieve subtype selectivity through allosteric effects but have significant agonistic activity that may lead to side effects like diarrhea.544,553”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [544]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Allosteric modulators typically attach to regions distinct from the orthosteric site of receptors, inducing conformational changes to regulate the affinity and/or efficacy of orthosteric ligands, or to directly modulate receptor activity with positive, negative, or neutral effects.542–545”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [544]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior
Picciotto, M. R., Higley, M. J., & Mineur, Y. S. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.036 · Cited by 1,404
Human Memory and the Cholinergic System: A Relationship to Aging?
Drachman, D. A. (1974) · Archives of Neurology · doi:10.1001/archneur.1974.00490320001001 · Cited by 1,397
Hulme, E. C., Birdsall, N. J. M., & Buckley, N. J. (1990) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.30.040190.003221 · Cited by 1,338
NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
A 5-month, randomized, placebo-controlled trial of galantamine in AD
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., Ding, C., & the Galantamine USA- Study Group (2000) · Neurology · doi:10.1212/wnl.54.12.2269 · Cited by 921
Activation and allosteric modulation of a muscarinic acetylcholine receptor
Kruse, A. C., Ring, A. M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hübner, H., Pardon, E., Valant, C., Sexton, P. M., et al. (2013) · Nature · doi:10.1038/nature12735 · Cited by 893
Structure and dynamics of the M3 muscarinic acetylcholine receptor
Kruse, A. C., Hu, J., Pan, A. C., Arlow, D. H., Rosenbaum, D. M., Rosemond, E., Green, H. F., Liu, T., Chae, P. S., Dror, R. O., et al. (2012) · Nature · doi:10.1038/nature10867 · Cited by 811
Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist
Haga, K., Kruse, A. C., Asada, H., Yurugi-Kobayashi, T., Shiroishi, M., Zhang, C., Weis, W. I., Okada, T., Kobilka, B. K., Haga, T., et al. (2012) · Nature · doi:10.1038/nature10753 · Cited by 792
Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes
Bonner, T. I., Young, A. C., Bran, M. R., & Buckley, N. J. (1988) · Neuron · doi:10.1016/0896-6273(88)90190-0 · Cited by 783
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Rogers, S. L. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.9.1021 · Cited by 773
Signalling bias in new drug discovery: detection, quantification and therapeutic impact
Kenakin, T., & Christopoulos, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3954 · Cited by 740
Mechanisms of signalling and biased agonism in G protein-coupled receptors
Wootten, D., Christopoulos, A., Marti-Solano, M., Babu, M. M., & Sexton, P. M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0049-3 · Cited by 724
Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., et al. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550160091022 · Cited by 692
Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
Shekhar, A., Potter, W. Z., Lightfoot, J., Lienemann, J., Dubé, S., Mallinckrodt, C., Bymaster, F. P., McKinzie, D. L., & Felder, C. C. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.06091591 · Cited by 560
Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions
Bennett, D. A., Schneider, J. A., Bienias, J. L., Evans, D. A., & Wilson, R. S. (2005) · Neurology · doi:10.1212/01.wnl.0000152982.47274.9e · Cited by 537
Localization of a family of muscarinic receptor mRNAs in rat brain
Buckley, N., Bonner, T., & Brann, M. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-12-04646.1988 · Cited by 476
Levey, A. I. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90300-r · Cited by 448
Arendt, T., Bigl, V., Tennstedt, A., & Arendt, A. (1985) · Neuroscience · doi:10.1016/0306-4522(85)90160-5 · Cited by 410
Muscarinic receptor signaling in the pathophysiology of asthma and COPD
Gosens, R., Zaagsma, J., Meurs, H., & Halayko, A. J. (2006) · Respiratory Research · doi:10.1186/1465-9921-7-73 · Cited by 409
Hersch, S., Gutekunst, C., Rees, H., Heilman, C., & Levey, A. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-05-03351.1994 · Cited by 404
Levey, A. I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13541 · Cited by 359
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
Brannan, S. K., Sawchak, S., Miller, A. C., Lieberman, J. A., Paul, S. M., & Breier, A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2017015 · Cited by 340
Crystal structures of the M1 and M4 muscarinic acetylcholine receptors
Thal, D. M., Sun, B., Feng, D., Nawaratne, V., Leach, K., Felder, C. C., Bures, M. G., Evans, D. A., Weis, W. I., Bachhawat, P., et al. (2016) · Nature · doi:10.1038/nature17188 · Cited by 335
Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology
Schmitz, T. W., Nathan Spreng, R., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., Jagust, W., Trojanowki, J. Q., Toga, A. W., et al. (2016) · Nature Communications · doi:10.1038/ncomms13249 · Cited by 335
Acetylcholinesterase inhibitors in Alzheimer’s disease
McGleenon, Dynan, & Passmore (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00026.x · Cited by 317
Current and future treatments in Alzheimer’s disease
Atri, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678581 · Cited by 309
Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus
Volpicelli, L. A., & Levey, A. I. (2004) · Progress in Brain Research · doi:10.1016/s0079-6123(03)45003-6 · Cited by 298
Ma, L., Seager, M. A., Wittmann, M., Jacobson, M., Bickel, D., Burno, M., Jones, K., Graufelds, V. K., Xu, G., Pearson, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900903106 · Cited by 285
Mufson, E. J., Bothwell, M., & Kordower, J. H. (1989) · Experimental Neurology · doi:10.1016/0014-4886(89)90124-6 · Cited by 279
Yamada, M., Lamping, K. G., Duttaroy, A., Zhang, W., Cui, Y., Bymaster, F. P., McKinzie, D. L., Felder, C. C., Deng, C.-X., Faraci, F. M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251542998 · Cited by 275
Fernández-Bachiller, M. I., Pérez, C., González-Muñoz, G. C., Conde, S., López, M. G., Villarroya, M., García, A. G., & Rodríguez-Franco, M. I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100329q · Cited by 268
Alexander, G. C., Emerson, S., & Kesselheim, A. S. (2021) · JAMA · doi:10.1001/jama.2021.3854 · Cited by 240
Shirey, J. K., Brady, A. E., Jones, P. J., Davis, A. A., Bridges, T. M., Kennedy, J. P., Jadhav, S. B., Menon, U. N., Xiang, Z., Watson, M. L., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3930-09.2009 · Cited by 237
Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System
Felder, C. C., Bymaster, F. P., Ward, J., & DeLapp, N. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990607u · Cited by 235
Foster, D. J., & Conn, P. J. (2017) · Neuron · doi:10.1016/j.neuron.2017.03.016 · Cited by 226
Seeger, T., Fedorova, I., Zheng, F., Miyakawa, T., Koustova, E., Gomeza, J., Basile, A. S., Alzheimer, C., & Wess, J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3581-04.2004 · Cited by 214
Rylett, R. J., Ball, M. J., & Colhoun, E. H. (1983) · Brain Research · doi:10.1016/0006-8993(83)90017-3 · Cited by 198
The Cholinergic System, the Adrenergic System and the Neuropathology of Alzheimer’s Disease
Bekdash, R. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031273 · Cited by 197
Muscarinic Acetylcholine Receptors (mAChRs) in the Nervous System: Some Functions and Mechanisms
Brown, D. A. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-010-9377-2 · Cited by 192
M2 and M4 Receptor Knockout Mice: Muscarinic Receptor Function in Cardiac and Smooth Muscle In Vitro
Stengel, P. W., Gomeza, J., Wess, J., & Cohen, M. L. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35366-2 · Cited by 190
Bridging the gap: bitopic ligands of G-protein-coupled receptors
Lane, J. R., Sexton, P. M., & Christopoulos, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.10.003 · Cited by 179
M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Jiang, S., Li, Y., Zhang, C., Zhao, Y., Bu, G., Xu, H., & Zhang, Y. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1406-z · Cited by 170
Aducanumab for Alzheimer’s disease?
Walsh, S., Merrick, R., Milne, R., & Brayne, C. (2021) · BMJ · doi:10.1136/bmj.n1682 · Cited by 159
Distribution and function of the muscarinic receptor subtypes in the cardiovascular system
Saternos, H. C., Almarghalani, D. A., Gibson, H., Meqdad, M. A., Antypas, R. B., Lingireddy, A., & AbouAlaiwi, W. A. (2017) · Physiological Genomics · doi:10.1152/physiolgenomics.00062.2017 · Cited by 153
Poulin, B., Butcher, A., McWilliams, P., Bourgognon, J.-M., Pawlak, R., Kong, K. C., Bottrill, A., Mistry, S., Wess, J., Rosethorne, E. M., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914801107 · Cited by 151
Self-citationMuscarinic and nicotinic cholinergic binding sites in alzheimer's disease cerebral cortex
Kellar, K. J., Whitehouse, P. J., Martino, A. M., Marcus, K. A., & Price, D. L. (1987) · Brain Research · doi:10.1016/0006-8993(87)91556-3 · Cited by 149
Flynn, D. D., Weinstein, D. A., & Mash, D. C. (1991) · Annals of Neurology · doi:10.1002/ana.410290305 · Cited by 146
Ztaou, S., Maurice, N., Camon, J., Guiraudie-Capraz, G., Goff, L. K., Beurrier, C., Liberge, M., & Amalric, M. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0873-16.2016 · Cited by 141
Sadot, E., Gurwitz, D., Barg, J., Behar, L., Ginzburg, I., & Fisher, A. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66020877.x · Cited by 139
Deletion of M 1 Muscarinic Acetylcholine Receptors Increases Amyloid Pathology In Vitro and In Vivo
Davis, A. A., Fritz, J. J., Wess, J., Lah, J. J., & Levey, A. I. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.6393-09.2010 · Cited by 137
Tricco, A. C., Ashoor, H. M., Soobiah, C., Rios, P., Veroniki, A. A., Hamid, J. S., Ivory, J. D., Khan, P. A., Yazdi, F., Ghassemi, M., et al. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15069 · Cited by 137
Atri, A., Molinuevo, J. L., Lemming, O., Wirth, Y., Pulte, I., & Wilkinson, D. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt160 · Cited by 126
Behavioral and Psychological Symptoms in Alzheimer’s Disease
Li, X.-L., Hu, N., Tan, M.-S., Yu, J.-T., & Tan, L. (2014) · BioMed Research International · doi:10.1155/2014/927804 · Cited by 122
The muscarinic M5 receptor: a silent or emerging subtype?
Eglen, R. M., & Nahorski, S. R. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703276 · Cited by 120
In vivo brain GPCR signaling elucidated by phosphoproteomics
Liu, J. J., Sharma, K., Zangrandi, L., Chen, C., Humphrey, S. J., Chiu, Y.-T., Spetea, M., Liu-Chen, L.-Y., Schwarzer, C., & Mann, M. (2018) · Science · doi:10.1126/science.aao4927 · Cited by 118
Physostigmine restores3H-acetylcholine efflux from Alzheimer brain slices to normal level
Nilsson, L. M., Nordberg, A. K., Hardy, J., Wester, P. O., & Winblad, B. G. (1986) · Journal of Neural Transmission · doi:10.1007/bf01243353 · Cited by 116
Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease
Pereira, J. B., Hall, S., Jalakas, M., Grothe, M. J., Strandberg, O. T., Stomrud, E., Westman, E., van Westen, D., & Hansson, O. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104831 · Cited by 115
Digby, G. J., Noetzel, M. J., Bubser, M., Utley, T. J., Walker, A. G., Byun, N. E., Lebois, E. P., Xiang, Z., Sheffler, D. J., Cho, H. P., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0337-12.2012 · Cited by 113
Bodick, N. C., Offen, W., Shannon, H. E., Satterwhite, J. H., Lucas, R., van Lier, R., & Paul, S. M. (1997) · PubMed · Cited by 113
A Monod-Wyman-Changeux Mechanism Can Explain G Protein-coupled Receptor (GPCR) Allosteric Modulation
Canals, M., Lane, J. R., Wen, A., Scammells, P. J., Sexton, P. M., & Christopoulos, A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.314278 · Cited by 111
Ghoshal, A., Rook, J. M., Dickerson, J. W., Roop, G. N., Morrison, R. D., Jalan‐Sakrikar, N., Lamsal, A., Noetzel, M. J., Poslusney, M. S., Wood, M. R., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.189 · Cited by 111
Tsang, S. W. Y., Lai, M. K. P., Kirvell, S. L., Francis, P. T., Esiri, M. M., Hope, T., Chen, C., & Wong, P. T. ‐. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.07.010 · Cited by 106
Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance
Geula, C., Dunlop, S. R., Ayala, I., Kawles, A. S., Flanagan, M. E., Gefen, T., & Mesulam, M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15471 · Cited by 102
Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases
Felder, C. C., Goldsmith, P. J., Jackson, K. A., Sanger, H., Evans, D. A. P., Mogg, A. J., & Broad, L. M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.028 · Cited by 98
Brown, A. J. H., Bradley, S. J., Marshall, F. H., Brown, G. A., Bennett, K. A., Brown, J., Cansfield, J. E., Cross, D. M., de Graaf, C., Hudson, B. D., et al. (2021) · Cell · doi:10.1016/j.cell.2021.11.001 · Cited by 96
Self-citationMuscarinic Receptor Subtypes in the Lower Urinary Tract
Giglio, D., & Tobin, G. (2009) · Pharmacology · doi:10.1159/000209255 · Cited by 94
Davoren, J. E., Lee, C.-W., Garnsey, M., Brodney, M. A., Cordes, J., Dlugolenski, K., Edgerton, J. R., Harris, A. R., Helal, C. J., Jenkinson, S., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00544 · Cited by 85
AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer's Disease
Fisher, A., Bezprozvanny, I., Wu, L., Ryskamp, D. A., Bar-Ner, N., Natan, N., Brandeis, R., Elkon, H., Nahum, V., Gershonov, E., et al. (2016) · Neurodegenerative Diseases · doi:10.1159/000440864 · Cited by 83
Moran, S. P., Dickerson, J. W., Cho, H. P., Xiang, Z., Maksymetz, J., Remke, D. H., Lv, X., Doyle, C. A., Rajan, D. H., Niswender, C. M., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0033-9 · Cited by 83
M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss
Bradley, S. J., Bourgognon, J.-M., Sanger, H. E., Verity, N., Mogg, A. J., White, D. J., Butcher, A. J., Moreno, J. A., Molloy, C., Macedo-Hatch, T., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87526 · Cited by 81
Self-citationCrystal structure of the M 5 muscarinic acetylcholine receptor
Vuckovic, Z., Gentry, P. R., Berizzi, A. E., Hirata, K., Varghese, S., Thompson, G., van der Westhuizen, E. T., Burger, W. A. C., Rahmani, R., Valant, C., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914446116 · Cited by 80
Self-citationMuscarinic cholinoceptors in the human heart: demonstration, subclassification, and distribution
Deighton, N. M., Motomura, S., Borquez, D., Zerkowski, H. R., Doetsch, N., & Brodde, O. (1990) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00195052 · Cited by 78
Structure and activation of muscarinic acetylcholine receptors
Hulme, E. C., Lu, Z. L., Saldanha, J. W., & Bee, M. S. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310029 · Cited by 74
Coupling of ml Muscarinic Receptors to G Protein in Alzheimer Disease
Pearce, B. D., & Potter, L. T. (1991) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199100530-00002 · Cited by 74
Lamping, K. G., Wess, J., Cui, Y., Nuno, D. W., & Faraci, F. M. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000130661.82773.ca · Cited by 74
Sharma, V. K., Colecraft, H. M., Wang, D. X., Levey, A. I., Grigorenko, E. V., Yeh, H. H., & Sheu, S. (1996) · Circulation Research · doi:10.1161/01.res.79.1.86 · Cited by 73
Regulators of cholinergic signaling in disorders of the central nervous system
Winek, K., Soreq, H., & Meisel, A. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15332 · Cited by 73
Rook, J. M., Bertron, J. L., Cho, H. P., García-Barrantes, P. M., Moran, S. P., Maksymetz, J., Nance, K. D., Dickerson, J. W., Remke, D. H., Chang, S., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00131 · Cited by 71
Nawaratne, V., Leach, K., Felder, C. C., Sexton, P. M., & Christopoulos, A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.125096 · Cited by 70
Reduction of cerebrospinal fluid amyloid β after systemic administration of M1 muscarinic agonists
Beach, T. G., Walker, D. G., Potter, P. E., Sue, L. I., & Fisher, A. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02484-2 · Cited by 69
Vardigan, J. D., Cannon, C. E., Puri, V., Dancho, M., Koser, A. J., Wittmann, M., Kuduk, S. D., Renger, J. J., & Uslaner, J. M. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3813-x · Cited by 68
Allostery in GPCRs: ‘MWC’ revisited
Canals, M., Sexton, P. M., & Christopoulos, A. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.08.005 · Cited by 65
Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias
van der Westhuizen, E. T., Choy, K. H. C., Valant, C., McKenzie-Nickson, S., Bradley, S. J., Tobin, A. B., Sexton, P. M., & Christopoulos, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.606656 · Cited by 63
Self-citationDiverse Effects on M 1 Signaling and Adverse Effect Liability within a Series of M 1 Ago-PAMs
Rook, J. M., Abe, M., Cho, H. P., Nance, K. D., Luscombe, V. B., Adams, J. J., Dickerson, J. W., Remke, D. H., García-Barrantes, P. M., Engers, D. W., et al. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00429 · Cited by 61
Shiozaki, K., Iseki, E., Hino, H., & Kosaka, K. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00638-4 · Cited by 60
Davoren, J. E., Garnsey, M., Pettersen, B., Brodney, M. A., Edgerton, J. R., Fortin, J.-P., Grimwood, S., Harris, A. R., Jenkinson, S., Kenakin, T., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00597 · Cited by 60
Sako, Y., Kurimoto, E., Mandai, T., Suzuki, A., Tanaka, M., Suzuki, M., Shimizu, Y., Yamada, M., & Kimura, H. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0168-8 · Cited by 60
Abdul-Ridha, A., Lane, J. R., Mistry, S. N., López, L., Sexton, P. M., Scammells, P. J., Christopoulos, A., & Canals, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.604967 · Cited by 56
Randomized, controlled, proof‐of‐concept trial of MK‐7622 in Alzheimer's disease
Voss, T., Li, J., Cummings, J., Farlow, M., Assaid, C., Froman, S., Leibensperger, H., Snow‐Adami, L., McMahon, K. B., Egan, M., et al. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.004 · Cited by 56
Allosteric modulation and functional selectivity of G protein-coupled receptors
Gao, Z.-G., & Jacobson, K. A. (2013) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2012.08.004 · Cited by 53
Ragozzino, M. E., Artis, S., Singh, A. T., Twose, T. M., Beck, J. E., & Messer, W. S. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.187625 · Cited by 53
Pharmacologic Management of Agitation in Patients with Dementia
McDermott, C. L., & Gruenewald, D. A. (2019) · Current Geriatrics Reports · doi:10.1007/s13670-019-0269-1 · Cited by 52
Nair, A. G., Castro, L. R. V., El Khoury, M., Gorgievski, V., Giros, B., Tzavara, E. T., Hellgren-Kotaleski, J., & Vincent, P. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.11.029 · Cited by 51
Hanyu, H., Shimizu, T., Tanaka, Y., Takasaki, M., Koizumi, K., & Abe, K. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000068785 · Cited by 50
Chambers, N., Meadows, S. M., Taylor, A., Sheena, E., Lanza, K., Conti, M. M., & Bishop, C. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.04.008 · Cited by 49
Puri, V., Wang, X., Vardigan, J. D., Kuduk, S. D., & Uslaner, J. M. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.03.029 · Cited by 48
Current Advances in Allosteric Modulation of Muscarinic Receptors
Jakubik, J., & El-Fakahany, E. E. (2020) · Biomolecules · doi:10.3390/biom10020325 · Cited by 48
Three FDA advisory panel members resign over approval of Alzheimer’s drug
Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n1503 · Cited by 48
Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs
Bradley, S. J., Molloy, C., Valuskova, P., Dwomoh, L., Scarpa, M., Rossi, M., Finlayson, L., Svensson, K. A., Chernet, E., Barth, V. N., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0453-9 · Cited by 47
Self-citationYeatman, H. R., Lane, J. R., Choy, K. H. C., Lambert, N. A., Sexton, P. M., Christopoulos, A., & Canals, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.536672 · Cited by 46
Rowe, W. B., O’Donnell, J.-P., Pearson, D., Rose, G. M., Meaney, M. J., & Quirion, R. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(03)00116-5 · Cited by 46
Muscarinic Agonists and Antagonists: Effects on Gastrointestinal Function
Ehlert, F. J., Pak, K. J., & Griffin, M. T. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-23274-9_15 · Cited by 44
Therapy for Insomnia and Circadian Rhythm Disorder in Alzheimer Disease
Ferini‐Strambi, L., Galbiati, A., Casoni, F. M., & Salsone, M. (2020) · Current Treatment Options in Neurology · doi:10.1007/s11940-020-0612-z · Cited by 41
Uslaner, J. M., Kuduk, S. D., Wittmann, M., Lange, H. S., Fox, S. V., Min, C., Pajkovic, N., Harris, D., Cilissen, C., Mahon, C., et al. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.245894 · Cited by 39
Abd‐Elrahman, K. S., Sarasija, S., Colson, T. L., & Ferguson, S. S. G. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15750 · Cited by 39
Chambon, C., Jatzke, C., Wegener, N., Gravius, A., & Danysz, W. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.10.011 · Cited by 38
Moehle, M. S., Bender, A. M., Dickerson, J. W., Foster, D. J., Qi, A., Cho, H. P., Donsante, Y., Peng, W., Bryant, Z., Stillwell, K. J., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00162 · Cited by 36
The M5muscarinic receptor as possible target for treatment of drug abuse
Raffa, R. B. (2009) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01059.x · Cited by 35
Jiang, J., & Jiang, H. (2015) · Neurological Sciences · doi:10.1007/s10072-015-2221-2 · Cited by 35
Uncoupling of M1 muscarinic receptor/G-protein interaction by amyloid β1–42
Janíčková, H., Rudajev, V., Zimčík, P., Jakubík, J., Tanila, H., El-Fakahany, E. E., & Doležal, V. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.014 · Cited by 35
Sullivan, N. R., Leventhal, L., Harrison, J., Smith, V. A., Cummons, T. A., Spangler, T. B., Sun, S.-C., Lu, P., Uveges, A. J., Strassle, B. W., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.118604 · Cited by 33
Heijman, J., Kirchner, D., Kunze, F., Chrétien, E. M., Michel, M. C., Voigt, N., Knaut, M., Michel, M. C., Ravens, U., & Dobrev, D. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.12.050 · Cited by 33
Davie, B. J., Valant, C., White, J. M., Sexton, P. M., Capuano, B., Christopoulos, A., & Scammells, P. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500556a · Cited by 32
Klawonn, A. M., Wilhelms, D., Lindström, S., Singh, A. K., Jaarola, M., Wess, J., Fritz, M., & Engblom, D. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00139 · Cited by 30
Khajehali, E., Valant, C., Jörg, M., Tobin, A. B., Conn, P. J., Lindsley, C. W., Sexton, P. M., Scammells, P. J., & Christopoulos, A. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.05.009 · Cited by 29
Self-citationMandai, T., Kasahara, M., Kurimoto, E., Tanaka, M., Suzuki, M., Nakatani, A., & Kimura, H. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.07.003 · Cited by 27
CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer’s Disease
Karami, A., Eriksdotter, M., Kadir, A., Almkvist, O., Nordberg, A. K., & Darreh‐Shori, T. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00239 · Cited by 27
Dwomoh, L., Rossi, M., Scarpa, M., Khajehali, E., Molloy, C., Herzyk, P., Mistry, S. N., Bottrill, A. R., Sexton, P. M., Christopoulos, A., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abm3720 · Cited by 24
Self-citationRomberg, C., Bartko, S. J., Wess, J., Saksida, L. M., & Bussey, T. J. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5065-7 · Cited by 23
Cholino‐ncRNAs modulate sex‐specific‐ and age‐related acetylcholine signals
Madrer, N., & Soreq, H. (2020) · FEBS Letters · doi:10.1002/1873-3468.13789 · Cited by 21
Peter, J., Mayer, I., Kammer, T., Minkova, L., Lahr, J., Klöppel, S., Grothe, M. J., & Orth, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-95573-8 · Cited by 21
Kondo, T., Nakajima, M., Teraoka, H., Unno, T., Komori, S., Yamada, M., & Kitazawa, T. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.08.034 · Cited by 20
Welt, T., Kulic, L., Hoey, S. E., McAfoose, J., Späni, C., Chadha, A. S., Fisher, A., & Nitsch, R. M. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150152 · Cited by 20
van der Westhuizen, E. T., Spathis, A., Khajehali, E., Jörg, M., Mistry, S. N., Capuano, B., Tobin, A. B., Sexton, P. M., Scammells, P. J., Valant, C., et al. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.111633 · Cited by 18
Self-citationMoran, S. P., Xiang, Z., Doyle, C. A., Maksymetz, J., Lv, X., Faltin, S., Fisher, N. M., Bender, A. M., Niswender, C. M., Rook, J. M., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aax2057 · Cited by 18
Wienrich, M., Ceci, A., Ensinger, H. A., Gaida, W., Mendla, K. D., Osugi, T., Raschig, A., & Weiser, T. W. (2002) · Drug Development Research · doi:10.1002/ddr.10085 · Cited by 17
Broad, L. M., Sanger, H., Mogg, A. J., Colvin, E. M., Zwart, R., Evans, D. A. P., Pasqui, F., Sher, E., Wishart, G. N., Barth, V., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14510 · Cited by 16
Bakker, C., Tasker, T. C. G., Liptrot, J., Hart, E. P., Klaassen, E. S., Doll, R. J., Brown, G. A., Brown, A., Congreve, M., Weir, M., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00816-5 · Cited by 16
Enhancement of memory function in aged mice by a novel derivative of xanomeline
Cui, Y., Wang, D., Si, W., Lv, W., Niu, Y., Lei, X., Hu, Y., & Cao, X. (2008) · Cell Research · doi:10.1038/cr.2008.292 · Cited by 15
Effects of acetylcholine on the coronary artery.
Pm, V., & Cohen, R. A. (1984) · PubMed · Cited by 14
Altered Cerebral Blood Flow in Alzheimer's Disease With Depression
Li, R., Zhang, Y., Zhuo, Z., Wang, Y., Jia, Z., Sun, M., Zhang, Y., Li, W., Duan, Y., Yao, Z., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.687739 · Cited by 14
Role of muscarinic receptors in renal response to acetylcholine
Yun, J. C. H., Oriji, G. K., Gill, J. R., Coleman, B. R., Peters, J., & Keiser, H. R. (1993) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1993.265.1.f46 · Cited by 10
Jörg, M., Khajehali, E., van der Westhuizen, E. T., Choy, K. H. C., Shackleford, D. M., Tobin, A. B., Sexton, P. M., Valant, C., Capuano, B., Christopoulos, A., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.202000540 · Cited by 9
Self-citationBakker, C., van der Aart, J., Labots, G., Liptrot, J., Cross, D. M., Klaassen, E. S., Dickinson, S., Tasker, T. C. G., & Groeneveld, G. J. (2021) · Drugs in R&D · doi:10.1007/s40268-021-00352-5 · Cited by 5
Dwomoh, L., Rossi, M., Scarpa, M., Khajehali, E., Molloy, C., Herzyk, P., Mistry, S. N., Bottrill, A. R., Sexton, P. M., Christopoulos, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.30.454298 · Cited by 3
Self-citation(2000) · doi:10.1002/1531-8249(200012)48:6
Research works printed but not linked: 1
- Brannan, 2018, KarXT, a combination of the M1/M4 cholinergic receptor agonist xanomeline and trospium for the treatment of psychosis and cognitive impairment in schizophrenia: phase I studies
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Akyuz, E., Arulsamy, A., Aslan, F. S., Sarisözen, B., Guney, B., Hekimoglu, A., Yilmaz, B. N., Retinasamy, T., & Shaikh, M. F. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04333-y · Cited by 69
Tacrine-Based Hybrids: Past, Present, and Future
Bubley, A., Erofeev, A. S., Gorelkin, P. V., Beloglazkina, E. K., Majouga, A. G., & Krasnovskaya, O. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021717 · Cited by 53
Khedraoui, M., Abchır, O., Nour, H., Yamari, I., Errougui, A., Samadi, A., & Chtita, S. (2024) · Pharmaceuticals · doi:10.3390/ph17070830 · Cited by 60
Uwada, J., Nakazawa, H., Muramatsu, I., Masuoka, T., & Yazawa, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076508 · Cited by 48
Metadata
- Authors
- Dwomoh, L., Tejeda, G. S., & Tobin, A. B.
- Affiliations
- University of Glasgow (GB)
- Corresponding author
- Dwomoh, Louis
- Venue
- Neuronal Signaling
- Publisher
- Portland Press Ltd.
- Published
- 2022-04
- Volume
- 6
- Issue
- 1
- Pages
- NS20210004-NS20210004
- ISSN
- 2059-6553 (ISSN-L)
- PMC
- PMC9069568
- OpenAlex
- W4226325396
- Cited by
- 60
- References
- 146
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 20 · 2023: 8 · 2022: 3
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuronal Signaling (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- Alzheimer's disease, M1 muscarinic receptor, muscarinic receptor ligands, cholinergic neurotransmission, cognitive function, drug development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.